R6 Ballot (2nd Draft)
Medication DefinitionPublish-box (todo)
| Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: No defined compartments |
Raw Turtle (+ also see Turtle/RDF Format Specification)
Simple version of a product (more than basic), only using MedicinalProductDefinition, Ingredient and RegulatedAuthorization
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
[a fhir:MedicinalProductDefinition ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "equilidem-with-ing-and-auth"] ; #
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <p>\n <b>\n Generated Narrative\n </b>\n </p>\n <p>\n <b>\n Id\n </b>\n : equilidem-with-ing-and-auth\n </p>\n <p>\n <b>\n Identifier\n </b>\n : Equilidem25\n </p>\n <p>\n <b>\n Combined Pharmaceutical Dose Form\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/dosefom tablet}\">\n tablet\n </span>\n </p>\n <p>\n <b>\n Indication\n </b>\n : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n </p>\n <p>\n <b>\n Legal Status Of Supply\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/legalstatusofsupply POM}\">\n Prescription only medicine\n </span>\n </p>\n <p>\n <b>\n classification\n </b>\n :\n <span title=\"Codes: {http://www.whocc.no/atc/example B01A}\">\n B01A\n </span>\n </p>\n <p>\n <b>\n Ingredients\n </b>\n :\n </p>\n <blockquote>\n <p>\n <b>\n Role\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/ingredientType active}\">\n active\n </span>\n </p>\n <blockquote>\n <p>\n <b>\n substance\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/substances 123456}\">\n Equilidonium Phosphate\n </span>\n </p>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Presentation\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n 22 ml/1 tablet\n </td>\n </tr>\n </table>\n </blockquote>\n </blockquote>\n <blockquote>\n <p>\n <b>\n Role\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/ingredientType excipient}\">\n excipient\n </span>\n </p>\n <blockquote>\n <p>\n <b>\n substance\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/substances 456789}\">\n Calcium Carbonate\n </span>\n </p>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Presentation\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n 3 ml/tablet\n </td>\n </tr>\n </table>\n </blockquote>\n </blockquote>\n <h3>\n Names\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n ProductName\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n Equilidem 2.5 mg film-coated tablets\n </td>\n </tr>\n </table>\n <h3>\n Cross References\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Product\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n Link to generic equivalent\n </td>\n </tr>\n </table>\n <h3>\n Manufacturing Business Operations\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Manufacturer\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n <span>\n EquiliDrugCo Processing Inc.\n </span>\n </td>\n </tr>\n </table>\n </div>"
] ; #
fhir:contained ( [
a fhir:Ingredient ;
fhir:id [ fhir:v "EquilidoniumPhosphate" ] ;
fhir:status [ fhir:v "active" ] ;
fhir:for ( [
fhir:reference [ fhir:v "#" ]
] ) ;
fhir:role [
fhir:coding ( [
fhir:system [ fhir:v "http://example.org.uk/fhir/ingredientType"^^xsd:anyURI ] ;
fhir:code [ fhir:v "active" ]
] )
] ;
fhir:substance [
fhir:code [
fhir:concept [
fhir:coding ( [
fhir:system [ fhir:v "http://example.org.uk/fhir/substances"^^xsd:anyURI ] ;
fhir:code [ fhir:v "123456" ] ;
fhir:display [ fhir:v "Equilidonium Phosphate" ]
] )
]
] ;
fhir:strength ( [
fhir:presentation [
a fhir:Ratio ;
fhir:numerator [
fhir:value [ fhir:v "22"^^xsd:decimal ] ;
fhir:unit [ fhir:v "ml" ] ;
fhir:system [ fhir:v "http://unitsofmeasure.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "mL" ]
] ;
fhir:denominator [
fhir:value [ fhir:v "1"^^xsd:decimal ] ;
fhir:unit [ fhir:v "tablet" ]
]
]
] )
]
] [
a fhir:Ingredient ;
fhir:id [ fhir:v "CalciumCarbonate" ] ;
fhir:status [ fhir:v "active" ] ;
fhir:for ( [
fhir:reference [ fhir:v "#" ]
] ) ;
fhir:role [
fhir:coding ( [
fhir:system [ fhir:v "http://example.org.uk/fhir/ingredientType"^^xsd:anyURI ] ;
fhir:code [ fhir:v "excipient" ]
] )
] ;
fhir:substance [
fhir:code [
fhir:concept [
fhir:coding ( [
fhir:system [ fhir:v "http://example.org.uk/fhir/substances"^^xsd:anyURI ] ;
fhir:code [ fhir:v "456789" ] ;
fhir:display [ fhir:v "Calcium Carbonate" ]
] )
]
] ;
fhir:strength ( [
fhir:presentation [
a fhir:Ratio ;
fhir:numerator [
fhir:value [ fhir:v "3"^^xsd:decimal ] ;
fhir:unit [ fhir:v "ml" ] ;
fhir:system [ fhir:v "http://unitsofmeasure.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "mL" ]
] ;
fhir:denominator [
fhir:value [ fhir:v "1"^^xsd:decimal ] ;
fhir:unit [ fhir:v "tablet" ]
]
]
] )
]
] ) ; #
fhir:identifier ( [
fhir:system [ fhir:v "http://example.org.uk/fhir/product"^^xsd:anyURI ] ;
fhir:value [ fhir:v "Equilidem25" ]
] ) ; #
fhir:combinedPharmaceuticalDoseForm [
fhir:coding ( [
fhir:system [ fhir:v "http://example.org.uk/fhir/dosefom"^^xsd:anyURI ] ;
fhir:code [ fhir:v "tablet" ]
] )
] ; #
fhir:indication [ fhir:v "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."] ; #
fhir:legalStatusOfSupply [
fhir:coding ( [
fhir:system [ fhir:v "http://example.org.uk/fhir/legalstatusofsupply"^^xsd:anyURI ] ;
fhir:code [ fhir:v "POM" ] ;
fhir:display [ fhir:v "Prescription only medicine" ]
] )
] ; #
fhir:classification ( [
fhir:coding ( [
fhir:system [ fhir:v "http://www.whocc.no/atc/example"^^xsd:anyURI ] ;
fhir:code [ fhir:v "B01A" ]
] )
] ) ; #
fhir:name ( [
fhir:productName [ fhir:v "Equilidem 2.5 mg film-coated tablets" ]
] ) ; #
fhir:crossReference ( [
fhir:product [
fhir:reference [
fhir:reference [ fhir:v "MedicinalProductDefinition/genericEquilidonium" ]
]
]
] ) ; #
fhir:operation ( [
fhir:organization ( [
fhir:display [ fhir:v "EquiliDrugCo Processing Inc." ]
] ) # licence holder uses RegulatedAuthorization
] )] . #
# -------------------------------------------------------------------------------------
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR ®© HL7.org 2011+. FHIR R6 hl7.fhir.core#6.0.0-ballot2 generated on Mon, Aug 12, 2024 16:59+0800.
Links: Search |
Version History |
Contents |
Glossary |
QA |
Compare to R5 |
|
Propose a change